Implantable ocular drug delivery devices

Patent metadata

Field	Value
Publication number	US-11617680-B2
Application number	US-201716091493-A
Country	US
Kind code	B2
Filing date	Apr 5, 2017
Priority date	Apr 5, 2016
Publication date	Apr 4, 2023
Grant date	Apr 4, 2023

Abstract

An implantable device having a reservoir for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.

First claim

What is claimed is:

1. A drug delivery device configured to be at least partially implanted in an eye through the sclera, the device comprising:
a retention structure positioned near a proximal end region of the device comprising:
a proximal flange element defining an access port into the device; and
a neck having a proximal region and a distal extension, the proximal region of the neck having a major axis dimension and a minor axis dimension, such that upon implantation through a penetration site in the sclera of the eye the proximal flange element is configured to remain outside the sclera, the proximal region of the neck is configured to span the penetration site in the sclera, and the distal extension is configured to be positioned inside the sclera,

wherein the access port of the proximal flange element extends through the proximal region of the neck defining a trans-scleral access port region of the access port and extends through the distal extension of the neck defining a sub-scleral access port region of the access port;
a penetrable element coupled to and extending within at least a portion of the access port, wherein the penetrable element has a proximal end positioned within the proximal flange element, a first portion positioned within the trans-scleral access port region, and a second portion positioned within the sub-scleral access port region, wherein a maximum distance across the proximal end and the first portion along the major axis dimension of the neck are less than a maximum distance across the second portion along the major axis dimension of the neck;
a porous drug release element positioned in fluid communication with an outlet of the device; and
a reservoir having a volume configured to contain one or more therapeutic agents and to be in fluid communication with the outlet through the porous drug release element, wherein a proximal end of the reservoir forms a shoulder configured to capture scleral tissue in a region between an inner surface of the retention structure and an upper surface of the shoulder, and
wherein the device is configured to be at least partially inserted into the eye along an axis of insertion.

2. The device of claim 1 , wherein the reservoir is configured to enlarge from an insertion configuration having a first three-dimensional shape to an expanded configuration having a second three-dimensional shape.

3. The device of claim 2 , wherein a first portion of the volume of the reservoir in the expanded configuration enlarges away from the lens of the eye and is greater than a remaining portion of the volume.

4. The device of claim 3 , wherein the first portion and the remaining portion each remain outside the visual axis of the eye.

5. The device of claim 2 , wherein the device remains outside the visual axis in the expanded configuration.

6. The device of claim 2 , wherein the second three-dimensional shape is eccentrically positioned relative to the axis of insertion.

7. The device of claim 2 , wherein when the device is in the first three-dimensional shape a distal end region of the device is aligned with the axis of insertion, and when in the second three-dimensional shape the distal end region of the device is not aligned with the axis of insertion.

8. The device of claim 1 , wherein the reservoir is formed of a non-compliant material.

9. The device of claim 8 , wherein the non-compliant material of the reservoir expands from the first three-dimensional shape to the second three-dimensional shape, but does not stretch beyond the second three-dimensional shape.

10. The device of claim 1 , further comprising an elongated core element having a longitudinal axis extending from the proximal end region of the device to a distal end region of the device.

11. The device of claim 10 , wherein the drug release element is coupled to the elongated core element near the distal end region of the device and the retention structure is coupled to the elongated core element near the proximal end region of the device.

12. The device of claim 10 , wherein the elongated core element comprises an inner lumen and one or more openings extending through a wall of the elongated core element.

13. The device of claim 12 , wherein the inner lumen of the elongated core element is in fluid communication with the reservoir volume through the one or more openings.

14. The device of claim 1 , wherein the reservoir is formed of non-compliant material, the non-compliant material of the reservoir is collapsed around an elongated core element forming a first three-dimensional shape prior to filling the volume with the one or more therapeutic agents when the device is in an insertion configuration, and wherein the non-compliant material of the reservoir is enlarged away from the elongated core element forming a second three-dimensional shape upon filling the volume with the one or more therapeutic agents when the device is in an expanded configuration.

15. The device of claim 1 , wherein the proximal region of the neck is sized along a cross-section to fit the penetration site through the sclera such that the proximal region is narrowed compared to the distal extension.

16. The device of claim 1 , wherein the proximal region of the neck has a cross-sectional shape that is substantially cylindrical and an access port extending through the proximal region into the reservoir is substantially cylindrical or has a cross-sectional shape that is substantially lenticular forming a pair of outer pinched regions on either side of the major diameter.

17. The device of claim 1 , wherein the proximal region of the neck is flared and an access port extending through the proximal region into the reservoir is tapered.

18. The device of claim 1 , wherein a maximum distance across the proximal region of the neck along the minor axis dimension is shorter than a maximum distance across the distal extension, and wherein a maximum distance across the proximal region of the neck along the major axis dimension is longer than a maximum distance across the distal extension.

19. A drug delivery device configured to be at least partially implanted in an eye through the sclera, the device comprising:
a retention structure positioned near a proximal end region of the device comprising:
a proximal flange element defining an access port into the device; and
a neck having a proximal region and a distal extension, the proximal region of the neck having a major axis dimension and a minor axis dimension, such that upon implantation through a penetration site in the sclera of the eye, the proximal flange element is configured to remain outside the sclera, the proximal region of the neck is configured to span the penetration site in the sclera, and the distal extension is configured to be positioned inside the sclera,
wherein the access port of the proximal flange element extends through the proximal region of the neck defining a trans-scleral access port region of the access port and extends through the distal extension of the neck defining a sub-scleral access port region of the access port;

a penetrable element coupled to and extending within at least a portion of the access port, wherein the penetrable element has a proximal end positioned within the proximal flange element, a first portion positioned within the trans-scleral access port region and a second portion positioned within the sub-scleral access port region, wherein a maximum distance across the proximal end and the first portion along the major axis dimension of the neck [[being]]are less than a max

Assignees

• Forsight Vision4 Inc

Inventors

• Campbell Randolph E
• Sacherman Kevin W
• Bachelder Bradley G
• Erickson Signe
• Boyette Jeremy

Classifications

• A61F9/0017 Primary

  implantable in, or in contact with, the eye, e.g. ocular inserts · CPC title

• A61K9/0051

  Ocular inserts or implants · CPC title

• A61F2250/0068

  the pharmaceutical product being in a reservoir · CPC title

• A61F9/0026

  Ophthalmic product dispenser attachments to facilitate positioning near the eye · CPC title